As GLP-1 drugs reshape obesity and diabetes care, researchers are examining whether fractional dosing could ease side effects and extend treatment without sacrificing the broader benefits that make these therapies valuable.
Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Image Credit: Celso Pupo / Shutterstock
In a recent non-systematic narrative review published in the journal Cureus, researchers summarized current evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and discussed the possible benefits of microdosing these agents.
Obesity remains a significant health concern worldwide. The prevalence of generalized obesity among adults (viz., body mass index [BMI] > 30 kg/m2) and extreme obesity (viz., BMI > 40 kg/m2) has been increasing in the United States (US), while childhood obesity is defined using age- and sex-specific BMI thresholds. Data from a survey conducted in 2021–23 indicate that 21% of children and adolescents and 40% of adults had obesity in the US.
The development of GLP-1RAs has been a remarkable advancement in the treatment of obesity and diabetes. Exenatide was the first GLP-1RA approved for type 2 diabetes (T2D) in 2005, and the drug class has since expanded to include liraglutide, dulaglutide, and semaglutide. Nevertheless, demand for GLP-1RAs far exceeds supply, contributing to high costs and significant gaps in care.
The authors suggest that these pressures have encouraged greater use of medication microdosing. Although microdosing originally referred to sub-pharmacologically active doses used in drug-development studies, the review uses the term clinically to describe smaller, fractional doses of a medication that may allow patients to receive some therapeutic benefits while extending their use of the medication.
Clinical benefits of GLP-1RAs
GLP-1RAs modulate energy intake and promote satiety through agonism of the GLP-1 receptor. These agents also improve glycemic control by suppressing glucagon and stimulating insulin secretion. A recent umbrella review noted trends toward improvements in respiratory, renal, metabolic, endocrine, and cardiovascular outcomes, as well as cognitive function, with GLP-1RAs, suggesting that benefits may extend beyond weight reduction across multiple organ systems.
A meta-analysis reported that GLP-1RAs led to significant reductions in major adverse cardiovascular events (MACE) and mortality. Another meta-analysis showed that long-acting GLP-1RAs reduced MACE and improved a composite kidney outcome in patients with T2D. Moreover, an umbrella review reported that GLP-1RAs were associated with improvements in body weight, glycemic control, and various renal and cardiovascular outcomes, although the certainty of evidence was lower for some cardiovascular and kidney outcomes.
Furthermore, a case report of a 34-year-old woman with type 2, stage III lipedema showed improvements after 30 days of treatment with low-dose tirzepatide, a dual GIP and GLP-1 receptor agonist, although a single case cannot establish treatment efficacy. A systematic review indicated that GLP-1RAs significantly improved one measure of motor function in people with Parkinson’s disease (PD), while other motor outcomes did not significantly improve and adverse events were more frequent.
Current dosing regimens of GLP-1RAs
Gradual dose titration is recommended for GLP-1RAs, such as liraglutide and semaglutide, to reduce the risk of adverse gastrointestinal (GI) effects. For obesity, semaglutide is initiated at 0.25 mg once weekly for 4 weeks, then increased to 0.5 mg, 1 mg, and 1.7 mg once weekly for 4 weeks each, until reaching 2.4 mg after 16 weeks.
By contrast, liraglutide is initiated at 0.6 mg/day for the first week, then at 1.2 mg/day, 1.8 mg/day, and 2.4 mg/day for one week each, reaching 3 mg/day after four weeks. For diabetes treatment, semaglutide and liraglutide can be dosed up to 2 mg and 1.8 mg, respectively, as weekly and daily subcutaneous injections. Tirzepatide has identical dosing for both T2D and obesity: start at 2.5 mg once weekly, then increase to 5 mg once weekly four weeks later, with further 2.5 mg increases every four weeks to a maximum of 15 mg weekly.
Tolerability and microdosing of GLP-1RAs
The primary limitation of long-term GLP-1RA use is adverse GI effects, such as nausea, diarrhea, constipation, and vomiting, which are also among the leading causes of treatment discontinuation. More severe adverse effects, including intestinal obstruction, delayed gastric emptying, and biliary disease, have been variably reported, with inconsistent evidence regarding these complications. Notably, tolerability has often been found to improve over time, suggesting that fractional or lower dosing may support treatment continuity.
The authors propose microdosing as a tolerability-first framework, enabling clinicians to personalize dosing to individual patients and potentially minimize treatment barriers. It could be a valuable option for people with exaggerated pharmacological responses to a standard dose and for those with high sensitivity to adverse effects. Nevertheless, studies on the effects of microdosing GLP-1RAs are extremely limited, and the established benefits of standard GLP-1RA doses cannot be assumed to persist with fractional dosing. Dose-escalation trials suggest a strong therapeutic response in some patients at submaximal doses.
A prospective observational study found improvements in body weight, BMI, triglycerides, glycated hemoglobin, and low-density lipoprotein cholesterol with low-dose tirzepatide among non-diabetic adults with obesity. Further, a pooled analysis of phase III trials assessing once-weekly semaglutide doses of 0.5 mg and 1 mg indicated improved tolerability over time and reduced sensitivity to adverse GI events with long-term exposure. However, these studies provide indirect support rather than direct evidence from trials specifically designed to test a microdosing strategy.
Concluding remarks
Collectively, although microdosing emerged as a pharmacokinetic tool in drug development, the authors describe it as an emerging pragmatic approach in clinical practice. Microdosing, alongside other treatment modalities, may better support patients in reaching their health goals and improve their quality of life. However, there is limited direct evidence on microdosing GLP-1RAs, warranting more research to confirm that fractional dosing helps maintain long-term benefits.
The review also notes that microdosing is an off-label approach and that fractional dosing with existing injection devices may raise sterility and safety considerations. The authors therefore recommend caution and clinician guidance before initiating a microdosing regimen.